Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Cambridge, UK, 7-8 April 2022

Ann Endocrinol (Paris). 2022 Dec;83(6):461-468. doi: 10.1016/j.ando.2022.07.674. Epub 2022 Oct 4.

Abstract

Lipodystrophy syndromes are rare diseases with defects in the development or maintenance of adipose tissue, frequently leading to severe metabolic complications. They may be genetic or acquired, with variable clinical forms, and are largely underdiagnosed. The European Consortium of Lipodystrophies, ECLip, is a fully functional non-profit network of European centers of excellence working in the field of lipodystrophies. It provides a favorable environment to promote large Europe-wide and international collaborations to increase the basic scientific understanding and clinical management of these diseases. It works with patient advocacy groups to increase public awareness. The network also promotes a European Patient Registry of lipodystrophies, as a collaborative research platform for consortium members. The annual congress organized gives an update of the findings of network research groups, highlighting clinical and fundamental aspects. The talks presented during the meeting in Cambridge, UK, in 2022 are summarized in these minutes.

Keywords: Antibody; Caveolin-1; EPHX1; Encephalopathy; Fatty acid; Lipodystrophy syndrome; Metreleptin; Registry; Seipin; Therapeutic education; Total body irradiation; miRNA.

Publication types

  • Clinical Conference

MeSH terms

  • Adipose Tissue
  • Humans
  • Lipodystrophy* / genetics
  • Lipodystrophy* / therapy
  • Syndrome
  • United Kingdom